Register now
Register to receive full, unrestricted access to our resources, regular updates and partnership opportunities
This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
This podcast focuses on collaborative working projects (CWPs) in breast cancer, exploring how partnership approaches can optimise patient care and support clinicians in delivering high-quality services.
Hosted by John Bingham from The Clarion Portfolio, this session brings together expert insights from Jeremy Dixon, Value & Access Marketing Director, and Helen Fotheringham, Solution & Service Design Lead, at Novartis UK. It also features perspectives from key team members at the Greater Manchester Cancer Alliance, shared through pre-recorded clips, exploring how the project aims to enhance breast cancer care and support service delivery across the region through the introduction of new breast cancer care coordinators.
The discussion highlights the considerations involved in implementing a successful CWP, and the impact of collaboration between industry and the NHS in improving patient outcomes.
Discover how this collaboration is supporting service improvement, helping to enhance patient experience and streamline care delivery.
This episode is part of our series exploring the impact of collaborative working in the UK. Discover the other episodes in the series below and hear more about these innovative partnerships in action.
Discover how partnership-led change between the pharmaceutical industry and the NHS is shaping the future of healthcare.
UK | June 2026 | FA-11644724 Fictional patient and healthcare professional images.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.